Orange marigold flowers

Research

Lutein and zeaxanthin: what research shows about the macular pigment

12 min read

29% of eyes with lutein, 31% with placebo: that is how often macular degeneration progressed to the late form within 5 years in the largest trial on lutein. The difference was not statistically significant.1 A measurement in the eye, the pigment density of the macula, does rise measurably from about 5 mg of lutein a day.2

Lutein and zeaxanthin are among the few natural pigments (carotenoids) that accumulate specifically in the human eye.

The reason lies in the macula, the area of sharpest vision in the retina. There both carotenoids are deposited and form the yellowish macular pigment.3 How much of it is present can be measured. Whether more pigment means better vision is a different question. This article keeps them apart: what was measured, in whom and with what result.

What are lutein and zeaxanthin?

Lutein and zeaxanthin are yellow plant pigments from the xanthophyll group, which also includes astaxanthin. The body cannot make them itself; they come from food.3

Exactly 3 carotenoids accumulate in the macula: lutein, zeaxanthin and meso-zeaxanthin. Meso-zeaxanthin is rarely found in food. It is believed to form in the macula itself from carotenoids taken in.3

Why does lutein accumulate in the eye in particular?

The retina binds lutein and zeaxanthin via dedicated binding and transport proteins.3 There the pigments perform 2 tasks that can be shown well in the laboratory:

  • A filter for blue light: they absorb high-energy, short-wave light before it reaches the sensory cells.
  • Antioxidants: they capture reactive oxygen compounds in a tissue exposed to a lot of light and oxygen.

Whether protection of the retina in humans follows from this is the actual research question, not the premise.3

Which foods contain lutein?

The main sources are dark green leafy vegetables, along with yellow and orange fruit and vegetables.3 Lutein is also readily available from eggs and pistachios. How much of it reaches the body depends on preparation and on the fat in the meal.4

Two fried eggs with fresh spinach on a plate
Lutein is found mainly in dark green leafy vegetables and is also readily available from eggs.

A 2017 review sets out meal plans that reach 5 or 10 mg a day from the diet alone.4 That is the order of magnitude used in many studies too. How diet and supplements relate to each other in general is covered in Healthy diet or supplements.

What is macular pigment optical density (MPOD)?

Macular pigment optical density (MPOD) describes how strongly the macular pigment absorbs light. It is the most common measurement in lutein studies because it changes within a few months.

A meta-analysis of 46 studies with 3,189 adults with healthy eyes found a clear gradient: below 5 mg a day, mostly from the diet, MPOD did not change significantly. From 5 mg it rose, most clearly from 20 mg.2 A second meta-analysis of 20 randomised trials (chance assigns the groups) saw the rise in healthy people and in people with macular degeneration alike.5

Macular pigment: a greater rise with a higher daily amount

Mean rise in MPOD after 3 to 12 months, adults with healthy eyes

Less than 5 mg a daymostly from the diet, not significant0.02
5 to less than 20 mg a day0.04
20 mg a day or more0.11
Source: Wilson et al. 2021, meta-analysis of 46 studies with 3,189 participants. MPOD measures pigment density, not visual performance.

Does lutein improve visual acuity or contrast vision?

Here the evidence gets thinner. A network meta-analysis of 38 randomised trials found that practically all combinations tested raised MPOD and contrast sensitivity. Visual acuity improved only with a combination of antioxidants, lutein and fatty acids. The authors rate the evidence as low.6

In people with age-related macular degeneration (AMD), a meta-analysis combined 9 randomised trials with 920 eyes. With 10 or 20 mg of lutein a day, MPOD, visual acuity and contrast sensitivity rose.7 In 59 healthy 18- to 25-year-olds, MPOD and contrast sensitivity rose over 1 year with 12 or 24 mg of macular carotenoids, compared with placebo (a dummy preparation).8

What studies on lutein and zeaxanthin have measured

Meta-analyses and large randomised trials, endpoints in the eye and beyond

Macular pigment (MPOD)46 studies, 3,189 adults with healthy eyesincrease measured
Contrast sensitivitynetwork meta-analysis, 38 trials, low certaintyincrease measured
Visual acuityonly with certain combinationsinconsistent
Progression of late AMDAREDS2, 4,203 participants, 5 yearsnot significant
Memory and thinkingAREDS2, 3,501 tested, 5 yearsno difference
Progression of short-sightedness9 small, short trialsnot established
Sources as in the sections below: Wilson 2021, Hu 2024, AREDS2 2013, Chew 2015, Martinez-Perez 2025. A measured effect is not an authorised health claim.

What does AREDS2 show on lutein and macular degeneration?

In industrialised countries AMD is one of the leading causes of blindness.4 The best evidence here is not for lutein but for the AREDS combination of vitamins C and E, beta-carotene and zinc. According to a Cochrane review it probably slows progression to late AMD, with moderate-certainty evidence.9 More on the individual components is in the articles on zinc and vitamin E.

Whether lutein adds anything was tested in AREDS2: 4,203 people at increased risk, 10 mg of lutein and 2 mg of zeaxanthin a day, for a median of 5 years. In the primary comparison, the addition did not significantly reduce progression to late AMD.1 For lutein and zeaxanthin alone, the Cochrane review summarises: a similar or slightly lower risk, with low-certainty evidence.9

AREDS2: late macular degeneration after 5 years

Share of eyes in which the disease progressed to the late form

Placebo31 %
Lutein 10 mg + zeaxanthin 2 mg29 %
Omega-3 (DHA + EPA)31 %
Lutein + zeaxanthin + omega-330 %
Source: AREDS2 Research Group 2013, 4,203 participants at increased risk, all groups also taking the AREDS formula. Lutein + zeaxanthin versus placebo: no statistically significant difference (P = 0.12).

A meta-analysis of 8 smaller studies found better visual acuity with lutein and zeaxanthin plus omega-3 fatty acids than in the control groups. The authors consider further studies necessary.10

Why did lutein replace beta-carotene?

AREDS2 produced a second finding: more lung cancers occurred with beta-carotene, mainly in former smokers. The research group therefore considered lutein and zeaxanthin a suitable replacement in the AREDS formula.1

The 10-year follow-up of 3,882 participants confirmed the increased lung cancer risk with beta-carotene. With lutein and zeaxanthin it was not significantly increased. In a direct comparison with beta-carotene, lutein and zeaxanthin did somewhat better on AMD progression. After the trial ended, however, all participants received lutein and zeaxanthin; the data are therefore an observation, not a new randomised comparison.11

Why lutein replaced beta-carotene

Lung cancer in AREDS2, participants per group, after about 5 years

With beta-carotene23 cases, mostly former smokers2.0%
Without beta-carotene11 cases0.9%
Sources: AREDS2 Research Group 2013; after 10 years, Chew et al. 2022: odds ratio for lung cancer 1.82 with beta-carotene and 1.15 with lutein and zeaxanthin (not significant).

Does lutein affect memory and concentration?

Whether lutein plays a role beyond the eye is also being studied. A meta-analysis of randomised, placebo-controlled trials found no significant difference for attention, executive function and memory. In the change from baseline, the authors saw a possible contribution to maintaining memory and executive function.12

The largest randomised trial on the question is again AREDS2: in 3,501 people tested, with an average age of 72.7, cognitive decline over 5 years did not differ between lutein and placebo.13

What is known about diabetic retinopathy and glaucoma?

There are systematic reviews by the same research group on both conditions. For diabetic retinopathy the strongest findings come from laboratory and animal models; observational studies found less macular pigment in diabetes, and early small intervention studies found higher pigment levels.14

In glaucoma, more macular pigment was mostly associated with better visual performance in observational studies.15 An association is not yet proof of an effect. One co-author of both reviews gives a company (ZeaVision) as his affiliation.14,15

What do studies show on short-sightedness and tired eyes?

A 2025 systematic review found 9 randomised trials on nutrients and short-sightedness (myopia). Carotenoids such as lutein, zeaxanthin and astaxanthin slightly improved MPOD and symptoms of visual fatigue. No consistent, clinically meaningful slowing of short-sightedness was found. The trials were small, heterogeneous and short.16

How much lutein was used in studies?

  • 10 mg lutein and 2 mg zeaxanthin a day in AREDS2, over 5 years.1
  • 10 or 20 mg lutein in the trials in AMD.7
  • 12 or 24 mg of macular carotenoids in young healthy people.8
  • From 5 mg MPOD rose measurably in the meta-analysis, most clearly from 20 mg.2

Is lutein safe, and is there an upper limit?

In 2010 the European Food Safety Authority (EFSA) set an acceptable daily intake (ADI) of 1 mg per kilogram of body weight for lutein from Aztec marigold as a food additive (E 161b). For 70 kg that works out at 70 mg a day. The value is set cautiously because long-term studies are lacking.17 The study amounts of 10 to 24 mg are below it.

In the 10-year follow-up of AREDS2, the lung cancer risk with lutein and zeaxanthin was not significantly increased.11 For mortality, the Cochrane review found little or no difference, with very low-certainty evidence.9

Why does lutein usually come from the Aztec marigold?

Lutein in food supplements is mostly obtained from the flowers of the Aztec marigold (Tagetes erecta). A crystalline lutein product from this extract contains around 86% lutein and zeaxanthin.18 EFSA assessed lutein from Tagetes erecta with at least 80% carotenoids.17

Orange marigold flowers and plucked petals
The usual source of lutein for food supplements is the marigold Tagetes erecta, not the pot marigold Calendula officinalis.

In German the plant is called Studentenblume and is often confused with the pot marigold (Ringelblume). That is a different plant, Calendula officinalis.

Is there an authorised health claim for lutein?

No. In 2011 EFSA assessed claims submitted for lutein, including one on normal vision.19 Lutein does not appear in the EU list of authorised health claims.20 A study result is not an authorised health claim. What makes the difference is explained in the article on EU health claims.

Key takeaways

  • Together with meso-zeaxanthin, lutein and zeaxanthin form the macular pigment of the retina. They come from leafy vegetables, eggs and pistachios.
  • From about 5 mg a day macular pigment density rises measurably, most clearly from 20 mg.
  • Contrast vision and visual acuity: individual improvements, low evidence overall.
  • AREDS2: lutein and zeaxanthin did not significantly reduce progression of late AMD in the primary comparison. They replaced beta-carotene in the AREDS formula because of the lung cancer risk.
  • Memory and short-sightedness: no benefit established.
  • There is no authorised health claim for lutein.

Sources

  1. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA, 2013.
  2. Wilson LM, Tharmarajah S, Jia Y, et al. The Effect of Lutein/Zeaxanthin Intake on Human Macular Pigment Optical Density: A Systematic Review and Meta-Analysis. Advances in Nutrition, 2021.
  3. Bernstein PS, Li B, Vachali PP, et al. Lutein, zeaxanthin, and meso-zeaxanthin: The basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease. Progress in Retinal and Eye Research, 2016.
  4. Eisenhauer B, Natoli S, Liew G, Flood VM. Lutein and Zeaxanthin-Food Sources, Bioavailability and Dietary Variety in Age-Related Macular Degeneration Protection. Nutrients, 2017.
  5. Ma L, Liu R, Du JH, et al. Lutein, Zeaxanthin and Meso-zeaxanthin Supplementation Associated with Macular Pigment Optical Density. Nutrients, 2016.
  6. Hu W, Seah V, Huang V, Kim JE. Effect of Antioxidant Supplementation on Macular Pigment Optical Density and Visual Functions: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Advances in Nutrition, 2024.
  7. Feng L, Nie K, Jiang H, Fan W. Effects of lutein supplementation in age-related macular degeneration. PLoS One, 2019.
  8. Stringham JM, O'Brien KJ, Stringham NT. Contrast Sensitivity and Lateral Inhibition Are Enhanced With Macular Carotenoid Supplementation. Investigative Ophthalmology & Visual Science, 2017.
  9. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database of Systematic Reviews, 2023.
  10. Csader S, Korhonen S, Kaarniranta K, Schwab U. The Effect of Dietary Supplementations on Delaying the Progression of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. Nutrients, 2022.
  11. Chew EY, Clemons TE, Agrón E, et al. Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. JAMA Ophthalmology, 2022.
  12. Li J, Abdel-Aal ESM. Dietary Lutein and Cognitive Function in Adults: A Meta-Analysis of Randomized Controlled Trials. Molecules, 2021.
  13. Chew EY, Clemons TE, Agrón E, et al. Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial. JAMA, 2015.
  14. Lem DW, Gierhart DL, Davey PG. A Systematic Review of Carotenoids in the Management of Diabetic Retinopathy. Nutrients, 2021.
  15. Lem DW, Gierhart DL, Davey PG. Carotenoids in the Management of Glaucoma: A Systematic Review of the Evidence. Nutrients, 2021.
  16. Martinez-Perez C, Oliveira AP. Nutritional Supplementation for Myopia Prevention and Control: A Systematic Review of Randomized Controlled Trials. Nutrients, 2025.
  17. EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS). Scientific Opinion on the re-evaluation of lutein (E 161b) as a food additive. EFSA Journal, 2010.
  18. Kruger CL, Murphy M, DeFreitas Z, et al. An innovative approach to the determination of safety for a dietary ingredient derived from a new source: case study using a crystalline lutein product. Food and Chemical Toxicology, 2002.
  19. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to lutein and protection of DNA, proteins and lipids from oxidative damage (ID 3427), protection of the skin from UV-induced (including photo oxidative) damage (ID 1605, 1779) and maintenance of normal vision (ID 1779, 2080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal, 2011.
  20. European Union. Commission Regulation (EU) No 432/2012 establishing a list of permitted health claims made on foods, Annex. Official Journal of the European Union L 136, 25.05.2012.

ATLAS All-in-One - 35 ingredients, 4 capsules, once a day.